Home COVID-19 updates The National Aerospace Laboratories, abbreviated as NAL, will soon begin the human...

The National Aerospace Laboratories, abbreviated as NAL, will soon begin the human clinical trial of the indigenously developed non-invasive ventilator, named “SwasthVayu” to treat COVID-19 patients.

The National Aerospace Laboratories, abbreviated as NAL, will soon begin the human clinical trial of the indigenously developed non-invasive ventilator, named “SwasthVayu” to treat COVID-19 patients.

The human trials of this Made in India ventilator of the non-invasive variety is supposed to begin at the Manipal Hospital (Bengaluru). The Manipal Hospital had also collaborated with NAL in the development of this ventilator. It is being claimed that the development of this ventilator took only 36 days.

This ventilator can be used for COVID-19 patients, as well as patients suffering from respiratory diseases and heart problems.

SwasthVayu has been developed by NAL, which is a part of the Council of Scientific and Industrial Research (CSIR), in collaboration with Dr. Satyanarayana Mysore, head of the Pulmonology Respiratory and Sleep Medicine at Manipal Hospital, and Dr. Anurag Agarwal, Director of CSIR – Institute of Genomics and Integrative Biology.

The institute has said that the ventilator has been tested on artificial models of human lungs, yielding successful results.

The institute has said that an acute shortage of ventilators has been felt during this COVID-19 crisis, and this indigenously developed ventilator will help mitigate this shortage.

This site uses Akismet to reduce spam. Learn how your comment data is processed.